Atria Investments Inc Has $3.87 Million Position in IQVIA Holdings Inc. (NYSE:IQV)

Atria Investments Inc reduced its holdings in shares of IQVIA Holdings Inc. (NYSE:IQV) by 3.4% during the 4th quarter, Holdings Channel.com reports. The fund owned 19,705 shares of the medical research company’s stock after selling 699 shares during the period. Atria Investments Inc’s holdings in IQVIA were worth $3,872,000 at the end of the most recent reporting period.

Other institutional investors have also made changes to their positions in the company. Capital Performance Advisors LLP acquired a new stake in shares of IQVIA during the 3rd quarter valued at about $27,000. Avior Wealth Management LLC boosted its position in IQVIA by 117.6% in the third quarter. Avior Wealth Management LLC now owns 161 shares of the medical research company’s stock valued at $38,000 after buying an additional 87 shares in the last quarter. Synergy Asset Management LLC acquired a new position in IQVIA in the fourth quarter valued at about $33,000. Assetmark Inc. boosted its position in IQVIA by 612.5% in the third quarter. Assetmark Inc. now owns 228 shares of the medical research company’s stock valued at $54,000 after buying an additional 196 shares in the last quarter. Finally, Ashton Thomas Securities LLC acquired a new position in IQVIA in the third quarter valued at about $57,000. 89.62% of the stock is currently owned by institutional investors and hedge funds.

Analyst Upgrades and Downgrades

IQV has been the subject of a number of research analyst reports. Stephens initiated coverage on shares of IQVIA in a research note on Friday, December 20th. They issued an “overweight” rating and a $250.00 target price for the company. UBS Group dropped their target price on shares of IQVIA from $260.00 to $255.00 and set a “buy” rating for the company in a research note on Friday, February 7th. Morgan Stanley boosted their price target on shares of IQVIA from $245.00 to $250.00 and gave the stock an “overweight” rating in a research note on Tuesday, February 11th. Leerink Partners reissued an “outperform” rating and set a $248.00 price target (down from $260.00) on shares of IQVIA in a research note on Tuesday, November 19th. Finally, Stifel Nicolaus dropped their price target on shares of IQVIA from $273.00 to $261.00 and set a “buy” rating for the company in a research note on Friday, February 7th. Four equities research analysts have rated the stock with a hold rating, seventeen have issued a buy rating and one has assigned a strong buy rating to the company’s stock. According to data from MarketBeat.com, IQVIA currently has a consensus rating of “Moderate Buy” and an average price target of $249.05.

IQVIA Stock Up 3.4 %

IQVIA stock opened at $191.69 on Friday. The stock has a market capitalization of $33.80 billion, a PE ratio of 25.56, a price-to-earnings-growth ratio of 1.99 and a beta of 1.50. IQVIA Holdings Inc. has a twelve month low of $179.28 and a twelve month high of $261.73. The company has a quick ratio of 0.84, a current ratio of 0.84 and a debt-to-equity ratio of 2.12. The company has a 50 day moving average of $197.79 and a 200-day moving average of $213.11.

IQVIA (NYSE:IQV) last released its quarterly earnings results on Thursday, February 6th. The medical research company reported $2.90 earnings per share for the quarter, missing the consensus estimate of $3.11 by ($0.21). IQVIA had a net margin of 8.91% and a return on equity of 28.81%. On average, equities research analysts anticipate that IQVIA Holdings Inc. will post 10.84 EPS for the current fiscal year.

IQVIA Company Profile

IQVIA Holdings Inc engages in the provision of advanced analytics, technology solutions, and clinical research services to the life sciences industry in the Americas, Europe, Africa, and the Asia-Pacific. It operates through three segments: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions.